2023
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.Peer-Reviewed Original ResearchAcute myeloid leukemiaProstate cancerYears of ageAML progressionCancer progressionMyeloid leukemiaStratified survival analysisBiological agingHigh Gleason scoreCox proportional hazardsMarker of progressionProstate cancer progressionPersonalized therapeutic managementMultiple cancer typesAML incidenceOverall survivalPrognostic factorsGleason scoreTherapeutic managementPatient cohortRisk scorePatientsCancer aggressivenessChronological agingProportional hazards
2022
PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER
Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER. Journal Of Urology 2022, 207: e44. DOI: 10.1097/ju.0000000000002518.07.Peer-Reviewed Original ResearchAssociation of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2020
Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT).
Patel H, Srivastava A, Kim S, Singer E, Kim I, Jang T. Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT). Journal Of Clinical Oncology 2020, 38: e17052-e17052. DOI: 10.1200/jco.2020.38.15_suppl.e17052.Peer-Reviewed Original ResearchNonseminomatous germ cell tumorsRetroperitoneal lymph node dissectionLymph node countOverall survivalLN countStage IPrimary retroperitoneal lymph node dissectionTesticular nonseminomatous germ cell tumorsMultivariate analysisClinical stage ILymph node dissectionNational Cancer DatabaseSingle-center studyKaplan-Meier methodGerm cell tumorsNode countPT2 diseaseNode dissectionAnalytic cohortFavorable survivalCenter studyCell tumorsCancer DatabaseTherapeutic implicationsAcademic centersAccuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.
Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Journal Of Clinical Oncology 2020, 38: e17058-e17058. DOI: 10.1200/jco.2020.38.15_suppl.e17058.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsPrimary retroperitoneal lymph node dissectionCS I patientsNational Cancer DatabaseI patientsClinical stageOverall survivalClinical stagingTesticular nonseminomatous germ cell tumorsLymph node dissectionQuarter of patientsKaplan-Meier methodNodal disease burdenGerm cell tumorsUpstaging of diseaseCS1 patientsPathologic nodalPN3 diseasePrior chemotherapyNode dissectionIIA patientsMeier methodClinical outcomesTesticular cancerThe cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithm
2019
DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome
Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome. Clinical Genitourinary Cancer 2019, 17: 299-305.e1. PMID: 31204211, DOI: 10.1016/j.clgc.2019.05.004.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaDisease-free survivalAdvanced clear cell renal cell carcinomaDDR pathway alterationPathway alterationsLocalized Clear Cell Renal Cell CarcinomaDecreased disease-free survivalTCGA databaseShorter disease-free survivalCopy number alterationsTherapeutic agentsCox regression analysisT3-4 diseaseClear-Cell RenalRenal cell carcinomaDDR pathwaysPresence of mutationsT3a diseaseNeoadjuvant therapyOverall survivalPoor outcomeCell carcinomaCommon subtypeDisease progressionKidney cancerSimilar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerDDR pathway alterationProstate cancerPathway alterationsMetastatic castration-resistant prostate cancerSerum prostate-specific antigenHigh-risk diseaseMetastatic prostate cancerLower overall survivalPathway gene mutationsProstate-specific antigenPotential therapeutic targetUnited States National Cancer InstituteNational Cancer InstituteCRPC patientsCancer Genome AtlasOverall survivalSimilar incidenceTumor stageUnivariate analysisCancer InstituteTherapeutic targetSpecific antigenPARP inhibitorsPathway statusSurvival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma.
Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionOverall survival rateTesticular seminomaSurvival rateOverall survivalClinical stagePC settingsUnderwent retroperitoneal lymph node dissectionComprehensive community cancer programsFive-year overall survivalNational Cancer DatabaseCommunity cancer programsFirst-line treatmentLow-volume diseaseLymph node dissectionKaplan-Meier methodSurvival dataAvailable survival dataMajority of menNonseminoma histologyPrior chemotherapyNode dissectionSeminoma patientsFinal cohortOngoing trials
2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh risk
2017
MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Wang W, Kwon Y, Su L, Kim I, Lu S. MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal Of Urology 2017, 197: e765. DOI: 10.1016/j.juro.2017.02.1779.Peer-Reviewed Original ResearchLocal Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer
Parikh R, Byun J, Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer. The Prostate 2017, 77: 559-572. PMID: 28093791, DOI: 10.1002/pros.23294.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMetastatic prostate cancerLocal therapyOverall survivalProstate cancerRadiation therapyMultivariable Cox proportional hazards modelsLower co-morbidity scoreFive-year overall survivalCox proportional hazards modelAcademic/research programCo-morbidity scoreSuperior overall survivalNode-negative statusProspective clinical trialsKaplan-Meier methodLower T stagePatterns of careProportional hazards modelPropensity-score matchingPrimary diseaseT stageMedicare insuranceGleason scoreCancer Database
2014
Enzalutamide: looking back at its preclinical discovery
Ha Y, Kim I. Enzalutamide: looking back at its preclinical discovery. Expert Opinion On Drug Discovery 2014, 9: 837-845. PMID: 24820058, DOI: 10.1517/17460441.2014.918947.Peer-Reviewed Original ResearchConceptsCastration-recurrent PCaFirst-line therapyProstate cancerClinical developmentCastration-recurrent prostate cancerStandard first-line therapyAndrogen-AR axisAR agonist activityMetastatic prostate cancerAR nuclear translocationSelective AR modulatorsFurther clinical studiesAndrogen receptor antagonistPre-clinical discoveryDrug clinical developmentSequential therapyOverall survivalTargeted agentsReceptor antagonistClinical studiesPreclinical discoveryNew agentsAR modulatorsAgonist activityFDA approvalNovel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2
Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal Of Korean Medical Science 2014, 29: 351-356. PMID: 24616583, PMCID: PMC3945129, DOI: 10.3346/jkms.2014.29.3.351.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkersCarrier ProteinsEndopeptidasesFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedMuscle NeoplasmsNeoplasm InvasivenessNeoplasm StagingPlatelet Glycoprotein GPIb-IX ComplexPredictive Value of TestsRegression AnalysisRisk FactorsROC CurveUbiquitin ThiolesteraseUrinary Bladder NeoplasmsConceptsCancer-specific survivalCancer-specific deathBladder cancer patientsHigh expression groupExpression of USP18MIBC patientsCancer patientsExpression groupMuscle-invasive bladder cancer patientsCancer-specific survival ratesInvasive bladder cancer patientsMuscle-invasive bladder cancerLonger cancer-specific survivalMultivariate Cox regression analysisCox regression analysisInvasive bladder cancerSignificant risk factorsReliable prognostic markersMRNA expression levelsSurvival-related genesOverall survivalValidation cohortOriginal cohortLonger survivalPredicting Survival
2013
Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung J, Ha Y, Kim I. Radium Ra 223 dichloride in castration-resistant prostate cancer. Drugs Of Today 2013, 49: 483-90. PMID: 23977665, DOI: 10.1358/dot.2013.49.8.1968670.Peer-Reviewed Original ResearchConceptsRadium Ra 223 dichlorideCastration-resistant prostate cancerRa-223 dichlorideBone metastasesProstate cancerLarge randomized phase III trialsRandomized phase III trialMedian overall survivalPhase III trialsPlacebo groupIII trialsOverall survivalPreclinical studiesAntitumor effectsBone marrowCanine modelHigh biological effectPatientsMetastasisCancerBiological effectsKBq/Low toxicityRatsMarrow